Roche returned to Hansoh. The size of the check is only half the story

On October 19, 2026, China's Hansoh Pharma announced a second antibody-drug conjugate collaboration with Roche. The stated terms include a $400 million upfront payment, a $110 million first-anniversary payment, potentially more than $15 billion of additional development, regulatory and commercial milestones, and tiered royalties on future sales. This is a significant licensing agreement, but the headline figure does not describe revenue already collected.

Roche and Hansoh had signed another ADC deal about a year earlier. That agreement concerned one clinical-stage candidate, HS-20110, for development and commercialization outside mainland China, Hong Kong, Macau and Taiwan. The newly announced collaboration includes two Hansoh preclinical ADC programs and several additional programs directed at targets proposed by Roche.

The strategic shift is from licensing rights to one defined candidate toward building a contract that may generate and advance several future candidates. It does not mean Roche has acquired Hansoh or bought all rights to its ADC discovery platform. The scope is the specific programs and regional rights described in the announcement.

In 2025 Roche licensed one CDH17-targeted clinical candidate

Hansoh's October 17, 2025 announcement described HS-20110, a CDH17-targeting antibody-drug conjugate carrying a topoisomerase-inhibitor payload. It had entered a global Phase I program for colorectal and other solid tumors with trials under way in China and the United States. Early clinical activity was described by the developer, but the drug was not an approved treatment.

The Hong Kong Stock Exchange filing specifies an $80 million upfront payment and up to $1.45 billion in success-linked development, regulatory and commercialization milestones. Together, these add up to a potential $1.53 billion before tiered royalties. The higher figure was not cash received at signing and did not guarantee the drug would succeed.

The commercial asset in the 2025 contract was identifiable: exclusive rights to develop, manufacture and market HS-20110 in territories outside Greater China. Roche was acquiring rights to progress one known drug candidate. It was not buying every antibody, linker, payload or future compound that Hansoh might develop.

The 2026 agreement lets Roche propose targets for new programs

The latest agreement covers two Hansoh ADC candidates still in preclinical development plus multiple new programs using Hansoh's proprietary ADC technology against targets proposed by Roche. The announcement did not identify the targets, tumor types, exact number of additional programs, development timetables or per-program economics.

This is materially different from selecting an existing clinical candidate. Roche can bring target ideas into a program structure that uses Hansoh's capabilities to generate and advance ADCs. The value proposition shifts toward repeated research and early validation rather than a single transaction tied to a finished asset. The ability to generate promising candidates is a hypothesis to be tested, not proof of a particular success rate.

Importantly, access to Hansoh's proprietary platform for named or future agreed programs is not the same as acquiring ownership of the whole platform. The announcement does not establish a global transfer of its underlying intellectual property or blanket exclusivity over all future ADC inventions. Detailed selection authority and individual program rights remain undisclosed.

A $15 billion milestone ceiling is not $15 billion of earnings

The payment streams need to be separated. Hansoh is to receive $400 million upfront and $110 million at the agreement's first anniversary. It may earn more than $15 billion in additional milestones contingent on research and development, regulatory approvals and commercial outcomes across the programs, with tiered sales royalties added only if products reach the market.

Calling the entire milestone opportunity 'money Roche has paid' would be inaccurate. Some candidates may never reach human studies; others may fail to show an acceptable benefit-risk profile or receive regulatory approval. The announcement does not break down milestone amounts by program or disclose the likelihood that they will be achieved. Nor can the 2026 multi-program terms be used to derive a price per ADC comparable with the 2025 single-asset deal.

The structure distributes risk and economic upside over time. Hansoh secures a material initial payment while retaining exposure to future successful products. Roche need not pay the full theoretical value of several unproven candidates at the beginning. Both parties still depend on the actual progress and quality of the programs for the largest payments to materialize.

Hansoh will carry the work through global Phase Ia

The operational division of labor is unusually revealing. Under the 2026 deal, Hansoh leads early development until completion of global Phase Ia clinical trials. Roche then takes responsibility for subsequent development outside mainland China, Hong Kong, Macau and Taiwan. Hansoh retains the rights to develop, register and commercialize the programs in those four markets.

Phase Ia is an early human-testing stage ordinarily focused on initial safety, dosing and pharmacokinetic information. Completing it does not demonstrate market approval or establish that an ADC is clinically effective. What matters commercially is the transfer of a development program from the organization that generated the candidate to the partner capable of taking subsequent studies forward.

Such a handoff generally requires transferable clinical data, analytical methods, manufacturing and quality documentation, regulatory records and clearly allocated responsibilities. The companies have not disclosed that they are experiencing any particular handoff problem. These are the categories of capability a cross-company development arrangement would normally need to coordinate.

Geographic rights and U.S. participation make the agreement more than a one-way sale

Hansoh retains development, registration and commercialization rights across mainland China, Hong Kong, Macau and Taiwan. Roche has the ex-Greater-China development responsibility and related rights under the agreement. A collaboration described as global does not therefore mean the Chinese partner has sold away its entire domestic franchise.

Hansoh also has an option to select up to two programs and contribute to their development outside its retained territories. In exchange for such contributions, it may receive additional upside from those programs' commercialization in the United States. The public release did not say that any option has already been exercised, which programs might be selected or how the economics would be calculated.

That design leaves open several degrees of participation: ownership of Greater China commercialization rights, responsibility for early global clinical development and optional deeper involvement in selected ex-China programs. Whether these options have significant eventual value depends on scientific progress, contractual choices, approvals and sales that have not occurred.

Hansoh was licensing ADCs internationally before either Roche agreement

Two earlier GSK agreements provide useful context. In October 2023 GSK licensed Hansoh's B7-H4-targeted HS-20089 for markets outside Greater China. In December it added a separate B7-H3-targeted candidate, HS-20093, with a $185 million upfront payment. Hansoh's annual disclosure also recorded an $85 million upfront payment for the earlier HS-20089 deal. The two programs were separate, not a single undifferentiated license.

That history matters because it would be misleading to describe the Roche collaboration as Hansoh's first move from research into international licensing. It already had experience generating differentiated ADC candidates and contracting with multinational drugmakers. An enlarged Roche relationship is therefore better interpreted as another step in a pattern of external partnerships, not the first evidence of a viable research organization.

Yet repeated licensing is not the same as a proven commercial portfolio. Roche's confidential evaluation of Hansoh's platform has not been disclosed, nor are comparative success rates across partner programs available. The proper follow-up evidence is the number of candidates generated, actual trial progress, discontinued programs, cash payments realized and eventually approved products.

BANSEOG VIEW | From owning one molecule to managing a repeatable development interface

The 2025 transaction conveyed ex-Greater-China rights to one already identified clinical-stage ADC. The 2026 partnership reaches further back into the development process: existing preclinical assets, Roche-proposed targets, the technology needed to make additional candidates and Hansoh-led early human trials. That is a different unit of enterprise collaboration.

Execution would require more than excellent medicinal chemists. Antibody and payload design, linker chemistry, translational research, Phase Ia operations, CMC manufacturing and quality control, regulatory submissions, portfolio decisions and business development must join across corporate boundaries. This is an analysis of the capabilities implied by the contract, not a report of confirmed hiring at either company.

More than $15 billion in milestones remains an upside scenario tied to outcomes, and no underlying platform acquisition or blanket rights transfer has been established. What the agreement does show is that future value can be contracted around an organization's capacity to repeatedly generate, validate and hand off drug candidates—not just around the one drug it has already created. The next proof will come from programs moving through the clinic.

BANSEOG VIEW

BANSEOG VIEW | The value of a pipeline-building interface

In 2025 Roche licensed one defined clinical ADC outside Greater China. In 2026 it signed for existing preclinical candidates and multiple programs around targets it may propose to Hansoh. This does not transfer ownership of the underlying discovery platform.

The $400m upfront and $110m anniversary payment must be distinguished from more than $15bn in contingent milestone opportunities. No program-specific odds of success or realized future revenue are disclosed.

Executing this model requires a repeatable interface across target biology, antibody-linker-payload design, Phase Ia trials, CMC, regulatory readiness and business development. These are capability implications of the agreement, not confirmed new job openings.

SOURCES

Primary sources and references

Prepared Oct 20, 2026. Hansoh's Oct19 release details its second Roche ADC collaboration: two existing preclinical Hansoh programs plus multiple Roche-proposed targets using Hansoh's proprietary ADC platform; upfront $400m and first-anniversary $110m, more than $15bn potentially in development/regulatory/commercialization milestones plus tiered royalties. Hansoh leads global Phase Ia completion; Roche assumes later development outside mainland China, Hong Kong, Macau and Taiwan. Hansoh retains Greater China rights and an option to select and contribute to up to two ex-Greater-China programs in return for possible incremental U.S. commercial upside. Exercise of option not established. Hansoh Oct17 2025 release and HKEX Oct17 filing: HS-20110 CDH17-targeting clinical Phase I, $80m upfront plus up to $1.45bn contingent milestones ($1.53bn combined potential excluding royalties). GSK's separate HS-20089 and HS-20093 ADC licenses date to 2023. No public disclosure of the specific new 2026 targets, total program count, success likelihood, per-program economics, whole-platform acquisition or headcount changes. Oncology safety and efficacy remain subject to trials. Banseog capability and strategy interpretation must be distinguished from contractual fact. No unlicensed photos reused.